Pliant adds two board members with oncology development experience
Pliant Therapeutics appointed Flavia Borellini, Ph.D. to its board, adding oncology drug development leadership from Acerta Pharma and AstraZeneca.
Borellini previously led development of Calquence at Acerta Pharma, earlier ran AstraZeneca’s hematology franchise, previously held senior roles at Genentech.
Robert Iannone, M.D., M.S.C.E. also joined the board, bringing clinical development and regulatory experience from Jazz Pharmaceuticals and Immunomedics.
Iannone previously led immuno-oncology development at AstraZeneca, earlier ran oncology clinical development at Merck, including work on KEYTRUDA.
PLRX•
